Patient Organization
The patient comes first
For Bayer, one of the world's leading specialty pharmaceutical companies, patients' health always comes first. Exchanging ideas and information with patient organizations on the basis of mutual trust is an important component of our work.
Such cooperation helps us to understand the needs of patients as they come to terms with their illness. This enables us to gear our research and development to these needs and to continue working on improved, new drugs and therapies.
Bayer cooperates with patient organizations in all kinds of therapeutic areas. We attach great importance to transparency in this context and protect the independence of our cooperation partners.
Our principles
Cooperation between Bayer and patient organizations is based on the following principles.
- In order to provide patients with quality medical healthcare, a partnership with a patient organization pursues a specific objective concentrating on one or more of the following areas:
- raising awareness for certain diseases by improving diagnostic possibilities and preventive measures, knowing the patients' prospects and needs,
- understanding diseases and making sure that patients receive the best medical treatment available,
- improving the information provided to the patients,
- supporting medical innovations.
- Bayer and the patient organizations comply with international and national laws and regulations.
- Cooperation with a patient organization should neither influence decisions on a therapy nor promote or support specific therapies.
- Bayer respects the neutrality and independence of patient organizations. Cooperation is based on a partnership between equals in which transparency and clarity are fundamental principles. This is why we also provide information on the extent and nature of support.
Overview of cooperation with patient organizations in Europe in 2024
The following is a list of patient organizations with which Bayer and its affiliated companies in Europe cooperated in 2024.
Headquarters:
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 40.000 EUR |
| Purpose of interaction | Sponsorship of World Amyloidiosis Day |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 20.000 EUR |
| Purpose of interaction | Consultancy |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 2.769,30 EUR |
| Purpose of interaction | Disease awareness campaign on secondary stroke prevention |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 3.875 EUR |
| Purpose of interaction | Secondary Stroke Prevention Patient Council |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 1.600 EUR |
| Purpose of interaction | Disease awareness campaign on secondary stroke prevention |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 1.530 EUR |
| Purpose of interaction | Consultancy Agreement for Advisory Board Meeting (Stroke Pipeline) |
| Bayer Company | Bayer Consumer Care AG |
| Contract date | 2024 |
| Amount | 140.000 EUR |
| Purpose of interaction | Co-funding for a research project “HTA Mapping Project” |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 4.500 EUR |
| Purpose of interaction | Pharma Media Day |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 30.000 EUR |
| Purpose of interaction | Women and cardiovascular disease roundtable |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 560 EUR |
| Purpose of interaction | Consultancy Agreement for Advisory Board Meeting (Stroke Pipeline) |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 828 EUR |
| Purpose of interaction | Consultancy Agreement for Advisory Board Meeting (Stroke Pipeline) |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 13.668 EUR |
| Purpose of interaction | Fee for recruitment, and project support |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 13.668 EUR |
| Purpose of interaction | Partnership regarding the work of the advisory panel (Heart and Kidney Care Alliance) and the development/dissemination of unbranded educational materials to raise awareness of disease and disease progression in the cardio-renal-metabolic area. |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 5.322 EUR |
| Purpose of interaction | Creation of disease awareness materials |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 26.610 EUR |
| Purpose of interaction | Secondary Prevention of Stroke Support & Education Program |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 4.789,80 EUR |
| Purpose of interaction | ESOC AdBoard participation of patient representative |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 2.318,88 EUR |
| Purpose of interaction | Introduce Patients to H&KCA and learn their stories Discover any unmet needs in patient communication for disease awareness in diabetes, kidney and heart care Discuss a wider communication plan and how to move the engagement forwards, to best utilize initiative |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 2.661 EUR |
| Purpose of interaction | LOR – Patient Survey for Mended Hearts Members in Europe |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 6.046,50 EUR |
| Purpose of interaction | Support educational programme of work |
| Bayer Company | Bayer Consumer Care AG |
| Contract date | 2024 |
| Amount | 20.000 EUR |
| Purpose of interaction | SUSTAINING PARTNERSHIP 2024 |
| Bayer Company | Bayer Consumer Care AG |
| Contract date | 2024 |
| Amount | 20.000 EUR |
| Purpose of interaction | SUSTAINING PARTNERSHIP 2025 |
| Bayer Company | Bayer Consumer Care AG |
| Contract date | 2024 |
| Amount | 920 EUR |
| Purpose of interaction | Pharma Media Day |
| Bayer Company | Bayer Consumer Care AG |
| Contract date | 2024 |
| Amount | 368 EUR |
| Purpose of interaction | Team on a mission |
| Bayer Company | Bayer Consumer Care AG |
| Contract date | 2024 |
| Amount | 35.000 EUR |
| Purpose of interaction | Establishing a European Stroke Survivor Network |
| Bayer Company | Bayer Consumer Care AG |
| Contract date | 2024 |
| Amount | 360 EUR |
| Purpose of interaction | Participation in the Secondary Stroke Prevention Consensus Paper Delphi Panel |
| Bayer Company | Bayer Consumer Care AG |
| Contract date | 2024 |
| Amount | 240 EUR |
| Purpose of interaction | Participation in the Secondary Stroke Prevention Consensus Paper Delphi Panel |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 35.000 EUR |
| Purpose of interaction | Stroke prevention and advocacy |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 360 EUR |
| Purpose of interaction | Delphi panel consultancy Arlene Wilkie |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 240 EUR |
| Purpose of interaction | Delphi panel consultancy Hariklia Proios |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 40.000 EUR |
| Purpose of interaction | European Life After Stroke Forum 2025 |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 35.000 EUR |
| Purpose of interaction | Stroke prevention and advocacy |
| Bayer Company | Bayer AG |
| Contract date | 2024 |
| Amount | 80.000 EUR |
| Purpose of interaction | Patient Engagement Open Forum |
Europe:
Reports can be received from
UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania)
Alina Tikuišiene MD
Zirmunu str. 68A
LT-09124 Vilnius/Lithunia
Reports can be received from
UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania)
Alina Tikuišiene MD
Zirmunu str. 68A
LT-09124 Vilnius/Lithunia
Reports can be received from
Bayer AB- Bayer Scandinavia
Iina Wargh
Gustav III:s Boulevard 56
169 26 Solna
Reports can be received from
SC Bayer SRL
Bayer Pharmaceuticals Division
Sos. Pipera nr. 42., Sector 2
NUSCO Tower fl. 1,16,17
020112, Bucharest
Romania
Reports can be received from
Bayer Pharma d.o.o.
Jelena Tokanovic
Omladinskih brigada 88b
Belgrade
Reports can be received from
Bayer d.o.o.
Lucija Zlodi Gosnik
Bravnicarjeva 13
1000 Ljubljana
